CD86 and neoplasm: Ipilimumab is a monoclonal antibody against cytotoxic T lymphocyte antigen-4 (CTLA-4), which is known to inhibit binding of CD80 and CD86 molecules on antigen-presenting cells, thereby causing proliferation and activation of T cells and promoting presentation of tumor antigen [2].